Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galenea has received two Small Business Innovation Research (SBIR) grants to develop and discover therapeutics for cognitive deficits associated with schizophrenia.
Subscribe to our email newsletter
The first grant entitled ‘In Vitro Tools for Preclinical Analysis of Cognitive Therapies for Schizophrenia’ for the development of preclinical assays that accurately model human cognitive processes.
Galenea will use this technology to evaluate the desired electrophysiological effects of novel pro-cognitive therapeutic candidates on cortical neural networks for schizophrenia.
A second grant entitled ‘Novel Serotonergic, Pro-Cognitive Antipsychotic Therapies’ will support Galenea’s ongoing small molecule schizophrenia drug discovery program.